Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.8K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.8K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

4.9K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
4.9K
Erythropoiesis01:14

Erythropoiesis

5.4K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
5.4K
Hematopoiesis01:21

Hematopoiesis

7.9K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.9K
Vascular Resistance01:20

Vascular Resistance

9.1K
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
9.1K
Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

4.0K
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.

European journal of haematology·2026
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Blood advances·2026
Same author

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

The oncologist·2026
Same author

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Future oncology (London, England)·2026
Same author

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Cancer·2026

Related Experiment Video

Updated: Dec 7, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.2K

Is there a gender effect in polycythemia vera?

Francesca Palandri1, Barbara Mora2, Naseema Gangat3

  • 1Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy.

Annals of Hematology
|October 2, 2020
PubMed
Summary

Female sex may influence the biology and outcomes of polycythemia vera (PV), a myeloproliferative neoplasm. This review explores how gender impacts PV pathogenesis, symptoms, thrombotic risk, and prognosis.

Keywords:
GenderOutcomePolycythemia veraTherapy

More Related Videos

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

784
Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
08:07

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context

Published on: March 24, 2023

3.8K

Related Experiment Videos

Last Updated: Dec 7, 2025

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

10.2K
Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
08:53

Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes

Published on: January 10, 2025

784
Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context
08:07

Erythrocyte Sedimentation Rate: A Physics-Driven Characterization in a Medical Context

Published on: March 24, 2023

3.8K

Area of Science:

  • Hematology
  • Oncology
  • Medical Science

Background:

  • Philadelphia-negative chronic myeloproliferative neoplasms (MPN) are increasingly studied for gender-specific impacts.
  • Polycythemia vera (PV) presents with high thrombotic risk, systemic symptoms, and reduced survival.
  • Understanding gender differences in PV is crucial for personalized medicine.

Purpose of the Study:

  • To summarize current knowledge on the influence of female sex on polycythemia vera (PV) biology and clinical outcomes.
  • To review recent findings regarding gender-specific aspects of PV pathogenesis, diagnosis, and epidemiology.
  • To analyze the impact of female sex on symptom burden, thrombotic risk, treatment, and prognosis in PV patients.

Main Methods:

  • Literature review of recent studies on gender and polycythemia vera.
  • Synthesis of data on pathogenesis, diagnosis, epidemiology, and clinical presentation.
  • Analysis of treatment strategies and prognostic factors in female PV patients.

Main Results:

  • Evidence suggests female sex can impact PV biology and disease progression.
  • Gender differences are observed in symptom burden and thrombotic risk.
  • Treatment strategies and prognosis may vary between male and female PV patients.

Conclusions:

  • Female sex is a relevant factor influencing polycythemia vera (PV) clinical presentation and outcomes.
  • Further research is needed to fully elucidate gender-specific mechanisms in PV.
  • Tailoring treatment and management strategies based on gender may improve patient outcomes.